Seeking Alpha

AstraZeneca's (AZN -1.5%) $443M deal to acquire Omthera puts the U.K. company at "distinct...

AstraZeneca's (AZN -1.5%) $443M deal to acquire Omthera puts the U.K. company at "distinct commercial advantage" over Amarin (AMRN +0.3%), says Decision Resources' Paramjit Narang. Omthera's Epanova drug "offers higher and more constant bioavailability, and arguably better efficacy" in lowering triglyceride than Amarin's Vascepa, and it "lacks the gastrointestinal side effects of the market incumbent Lovaza," which is sold by GSK (GSK -2%). Narang reckons Epanova's annual sales could peak at $1B.
Comments (9)
  • CarolinaCowboy
    , contributor
    Comments (29) | Send Message
     
    These are the FACTS as quoted by Joe Z.
    1. Epanova ANCHOR data was worse than their MARINE equivalent data.
    2. On LDL, Epanova increased statistically significant 5% at the 2 gram dose, and at 1% sales and non-inferiority study, this is on their ANCHOR equivalent study.
    3. Vascepa reduced by 6%, a statistically significance. This is going to be a real problem for them.
    4. Lovaza results were better than Epanova yet even Lovaza failed to get their indication approved.
    5 Epanova non-HDL lowering is 1/3 to 1/2 of what Vascepa is doing. They continue to talk about 5% to 7% dropout in their study just due to side effects. Vascepa had 0% in their MARINE study, and had 2% in our ANCHOR study, which was less than placebo.
    6. They got lower Lp-PLA2 results and actually increase Apo B, whereas Vascepa decrease it.
    29 May 2013, 10:17 AM Reply Like
  • Iamstockgeniusjustaskme
    , contributor
    Comments (248) | Send Message
     
    Do understand that Joey has a stake in this, so I take what he says with a grain of salt. AZN bought this company over us, the question tha we can't answer s, why?

     

    Why hasn't Amarin released a press release yet regarding the outcome statment of Summer Street? I personally thnk Joey leaves a lot to be desired and to me his greed is why we haven't be sold.

     

    Love how people say that BP needs s, we Al's need them dont forget that.
    29 May 2013, 03:10 PM Reply Like
  • CarolinaCowboy
    , contributor
    Comments (29) | Send Message
     
    you are quoting "says Decision Resources' Paramjit Narang". Never heard of either of them. Get a REAL source. Do a little homework. LOL
    29 May 2013, 10:47 AM Reply Like
  • aqclovelita
    , contributor
    Comments (2) | Send Message
     
    As a cardiologist with 40 years experience in academic medicine and private practice, VASCEPA is far superior than Lovaza, or Epanova in reducing all types of lipids fractions and sub-fractions. Analysts are wrong, almost all of these analyst have no medical background in general nor cardiology background in particular. Dr. Niessen of Cleveland Clinic hardly sees any patient -- so he is off his mind to say that fish oils EPA such as VASCEPA has no role to play in reducing cardiovascular risks. I switched from LOVAZA to VASCEPA the moment Vascepa became available. I also switched my relatives and sons to Vascepa.
    29 May 2013, 12:30 PM Reply Like
  • moeschempf
    , contributor
    Comments (30) | Send Message
     
    If Mr. Narang had conducted more thorough research, he would see that Amarin has the distinct advantage in this market with Vascepa, especially when the ANCHOR indication is granted by the FDA.
    29 May 2013, 12:30 PM Reply Like
  • toucan
    , contributor
    Comments (16) | Send Message
     
    Good recall Carolina Cowboy.I think A-Z latched on because they hold Crestor. Amarin is going to have to partner up with a Phizer,which has Lipitor,or a Teva-like company to have access to a statin. for a combo product.The Anchor study is going to be the market maker as a sole way to control lipids.
    29 May 2013, 12:37 PM Reply Like
  • Iamstockgeniusjustaskme
    , contributor
    Comments (248) | Send Message
     
    How does using a generic statin combo helpful to Pfizer?
    29 May 2013, 03:12 PM Reply Like
  • stevie.atl
    , contributor
    Comments (24) | Send Message
     
    Helloooo?? Epanova has some undesirable side effects, including a big no no....it raises LDLC. Decision Resources seems to be lacking the basic information necessary to make such a bold claim. Are they forgetting that the Epanova hasn't been approved by the FDA yet and is significantly behind Vascepa in terms of approvals, patents, production sources and everything else??
    29 May 2013, 12:41 PM Reply Like
  • Iamstockgeniusjustaskme
    , contributor
    Comments (248) | Send Message
     
    Lovaza raises LDL, and it sells will. LDL as LNG as it s acceptable range is fine. It seems that many on both sides have talking points: Afib warning, LDL raising,...opposite view..,Amarin will lose key patents and go generic, GIA is not the way to go.
    29 May 2013, 03:14 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|